Sirtris Pharmaceuticals Inc.

Cambridge, Mass. • 617-252-6920 •

Exchange and Ticker: Nasdaq: SIRT

Filing Range: 5.00M shares @ $9.00 to $11.00

Offering Price: $10.00

Close on First Day: $10.76

Offering Size: $60.00M

Shares Outstanding: 26,789,114M

Underwriter: JPMorgan

Co-managers: JMP Securities LLC/ CIBC World Markets Inc./ Rodman & Renshaw Inc./ Piper Jaffray Cos.

Company Counsel: Ropes & Gray

Manager Counsel: Davis Polk & Wardwell

Auditor: Ernst & Young LLP

Market Capitalization on 5/31/07: $345.31M

Close price at current month end: $12.89


Develops molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. The company’s products are designed to mimic the beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins. Competitors include Abbott, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Lilly, Merck, and others.


Alexandria Real Estate Equities, Bessemer Venture Partners, Cardinal Partners, Cargill Ventures, Hercules Technology Growth Capital Inc., Hunt Ventures, Novartis Venture Fund, Polaris Venture Partners, Red Abbey Venture Partners, Skyline Ventures, Three Arch Partners, TVM Capital, Welcome Trust.

Source: Thomson Financial